Spondyloarthropathies News

Patients with axial spondyloarthritis who receive bimekizumab demonstrate sustained improvement through 52 weeks and a safety profile consistent with shorter trials, according to data published in the Annals of the Rheumatic Diseases.

Newly diagnosed psoriatic disease may bring with it a significantly increased risk for autoimmune disease incidences, according to a study.

Patients across health care specialties have in recent years come to expect some form of individually tailored care — or precision medicine — as part of their disease management.

Patients with axial spondyloarthritis and other related inflammatory diseases demonstrate common microbiome dysfunction characteristics, according to data published in Arthritis & Rheumatology.

The FDA has approved an intravenous formulation of Cosentyx for use in patients with psoriatic arthritis, ankylosing spondylitis and nonradiographic axial spondyloarthritis, according to a press release from Novartis.

The FDA has approved Abrilada as the second interchangeable biosimilar to adalimumab, according to a press release from Pfizer.

Although the current net price of adalimumab biosimilar Amjevita is lower for commercial health plans than that of the originator, it is nonetheless “more than double” what Humira cost at launch in 2003, according to a research letter.

A fully automated, machine learning model that predicts bone marrow edema in sacroiliac joint MRI could improve screening for spondyloarthritis and decrease diagnostic delay, according to data published in Arthritis & Rheumatology.

Patients with inflammatory rheumatic diseases are as likely as the general population to contract COVID-19, but are at a higher risk for severe outcomes, including hospitalization and death, according to data.

A new consensus definition for early axial spondyloarthritis indicates disease that has manifested symptoms for less than 2 years, according to a recommendation published in Annals of the Rheumatic Diseases.